EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)

Irene Tsung iD, David C Smith iD, Elisabeth I Heath iD, Frank Cackowski iD, Michael E Devitt iD, Thomas M Braun iD, Sarah Yentz, Charles B Nguyen iD, Arul M Chinnaiyan, Neel Shah, Simon Smith, Emma Dean iD und 5 weitere

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00457 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Irene Tsung und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Hematology and Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Prostatic Neoplasms, Castration-Resistant, Pyrimidines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Preclinical studies suggest the combination of the poly(adenosine diphosphate[ADP]-ribose) polymerase (PARP) inhibitor olaparib and the ataxia telangiectasia–mutated and Rad3-related (ATR) inhibitor ceralasertib has synergistic antitumor activity in homologous recombination proficient (HRP) and homologous recombination repair gene mutation (HRRm) patients. This study aims to determine the efficacy of olaparib plus ceralasertib in metastatic castration-resistant prostate cancer (mCRPC) with and without HRRm. PATIENTS AND METHODS Thirty-five HRP and 12 HRRm PARP inhibitor–naïve patients with mCRPC progressing on ≥1 line of therapy or previous androgen receptor pathway inhibitor were enrolled. Patients received olaparib (300 mg twice daily) and ceralasertib (160 mg once daily, days 1-7) in 28-day cycles. HRRm was defined as biallelic inactivation of BRCA2 or BRCA1 , monoallelic inactivation of ATM , or germline inactivation of any of these genes. The primary end point was disease response rate (dRR; confirmed prostate-specific antigen decline ≥50% and/or complete/partial radiographic response by RECIST v1.1) in HRP patients. Secondary end points included dRR in HRRm patients, progression-free survival (PFS), and safety/toxicity. Two-stage designs were used. RESULTS Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm patients responded. Median PFS was 8.2 months (95% CI, 5.3 to not reached) for HRP patients. Thirty-six percent of patients had ≥grade 3 toxicity, most commonly from anemia. Limitations include small, single-arm, nonrandomized trial design. CONCLUSION Combining ceralasertib with olaparib had limited activity in patients with HRP mCRPC. HRRm response rate was not greater than previous single-agent PARP inhibitor clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesPiperazinesProstatic Neoplasms, Castration-ResistantPyrimidinesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedMiddle AgedAtaxia Telangiectasia Mutated ProteinsPoly(ADP-ribose) Polymerase InhibitorsAged, 80 and overNeoplasm MetastasisIndolesMorpholinesSulfonamides

Substanzen

PhthalazinesPiperazinesolaparibceralasertibPyrimidinesAtaxia Telangiectasia Mutated ProteinsPoly(ADP-ribose) Polymerase InhibitorsATR protein, humanIndolesMorpholines

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Hematology and Oncology, Rogel Cancer Center, University of Michigan, Ann Arbor, MI.
  • Mayo Clinic Comprehensive Cancer Center, Rochester, NY.
  • Karmanos Cancer Institute, Detroit, MI.
  • University of Virginia Comprehensive Cancer Center, Charlottesville, VA.
  • University of Michigan School of Public Health, Ann Arbor, MI.
  • City of Hope Comprehensive Cancer Center, Irvine, CA.

ORCID-Profile: Irene Tsung, David C Smith, Elisabeth I Heath, Frank Cackowski, Michael E Devitt, Thomas M Braun, Charles B Nguyen, Emma Dean, Ulka Vaishampayan, Megan E V Caram, Phillip Palmbos, Joshi J Alumkal, Zachery R Reichert

Zitieren

APA

Tsung, I., Smith, D. C., Heath, E. I., Cackowski, F., Devitt, M. E., Braun, T. M., Yentz, S., Nguyen, C. B., Chinnaiyan, A. M., Shah, N., Smith, S., Dean, E., Vaishampayan, U., Caram, M. E. V., Palmbos, P., Alumkal, J. J., & Reichert, Z. R. (2025). Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP). JCO Precision Oncology. https://doi.org/10.1200/po-25-00457

Vancouver

Tsung I, Smith DC, Heath EI, Cackowski F, Devitt ME, Braun TM, et al. Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP). JCO Precision Oncology. 2025. doi:10.1200/po-25-00457

BibTeX
@article{Tsung2025,
  author = {Tsung, Irene and Smith, David C and Heath, Elisabeth I and Cackowski, Frank and Devitt, Michael E and Braun, Thomas M and Yentz, Sarah and Nguyen, Charles B and Chinnaiyan, Arul M and Shah, Neel and Smith, Simon and Dean, Emma and Vaishampayan, Ulka and Caram, Megan E V and Palmbos, Phillip and Alumkal, Joshi J and Reichert, Zachery R},
  title = {Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00457}
}
Kostenlos starten →